

BOUNDLESS POTENTIAL
At the University of Florida Center for Regenerative Medicine (CRM), clinical trials and collaboration are catalyzing the future of health care. The center’s expert team of affiliated faculty and clinicians, led by Dr. Keith March, is a national resource for research in regenerative medicine and cell-based therapy. By leveraging the power of the most comprehensive academic health center in the Southeast, the center is driving cross-disciplinary, boundary-breaking clinical trials and translating findings to the clinic to solve today’s most challenging unmet medical needs.
The center boasts established partnerships with researchers in UF’s six health-related colleges, the UF Clinical and Translational Science Institute, UF’s Institute of Food and Agricultural Sciences and other powerhouse research universities across the country. These connections reinforce a robust portfolio of clinical trials utilizing cell-based therapeutics in which the CRM is pioneering new national research that captures the innate healing power of umbilical cord lining-derived mesenchymal stem cells to help or even cure autoimmune and inflammatory diseases. At the same time, the CRM is building a pipeline of future clinicians, researchers and
medical experts with one of the only undergraduate regenerative medicine programs in the
country.
CLINICAL TRIAL OVERVIEW
Philanthropic support has been critical to the center’s advancement of clinical trials. By partnering with the JAR of Hope Foundation and RESTEM LLC, the CRM will be able to initiate an important trial for Duchenne Muscular Dystrophy(DMD). UF has already been selected as the clinical trial site and RESTEM, LLC has
received authorization from its Investigational New Drug Application to the FDA entitled “A phase 1, randomized, double-blind, placebo controlled Cross Over study to assess the safety, tolerability, and preliminary efficacy of Umbilical Cord Lining stem cells (ULSC) in Pediatric patients with duchenne’s muscular dystrophy (DMD)” to proceed with a Phase 1 trial in 12 patients. Additional support from the JAR of Hope Foundation will help translate Phase 1 and later Phase 2 trial with more answers as to if this will help these children with this debilitating disease. Applying the CRM’s research broadly, center leadership is seeing positive early results indicating that regenerative medicine might be a better course of treatment for some patients than immunosuppressive medicines with powerful side effects.
TOGETHER, WE WILL
The CRM is the ideal partner—a leading force in clinical trials allied with numerous departments across UF Health’s expansive academic health science center network. Results from the center’s research point the way to clear improvements in patient outcomes and have stimulated potentially game-changing developments in clinical care. From the smallest cells to entire communities, the UF Center for Regenerative Medicine is laser-focused on leveraging research that can address the symptoms of disease, trauma or degenerative illness for individual patients and broader populations. Few other regenerative medicine centers in the country can boast a research and clinical enterprise of comparable proportion—with deep expertise that stretches across the breadth of our efforts and leverages disciplines across our comprehensive research university. We appreciate your interest in supporting our shared vision to translate broad-based research into life-saving treatments for a multitude of debilitating diseases and ailments, especially DMD.